Mineralys Overview
- Year Founded
-
2019
- Status
-
Public
- Employees
-
51
- Stock Symbol
-
MLYS
- Share Price
-
$15.02
- (As of Monday Closing)
Mineralys General Information
Description
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Contact Information
Website
www.mineralystx.comCorporate Office
- 150 North Radnor Chester Roa
- Suite F200
- Radnor, PA 19087
- United States
Corporate Office
- 150 North Radnor Chester Roa
- Suite F200
- Radnor, PA 19087
- United States
Mineralys Timeline
Mineralys Stock Performance
As of 14-Jul-2025, Mineralys’s stock price is $15.02. Its current market cap is $979M with 65.2M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $15.02 | $14.49 | $8.24 - $18.38 | $979M | 65.2M | 778K | -$3.73 |
Mineralys Financials Summary
As of 31-Mar-2025, Mineralys has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 829,933 | 349,049 | 99,743 | |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (201,437) | (192,355) | (84,654) | (31,475) |
| Net Income | (188,513) | (177,810) | (71,898) | (29,799) |
| Total Assets | 354,941 | 205,903 | 251,636 | 114,442 |
| Total Debt | 0 | 0 | 0 | 0 |
Mineralys Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Mineralys Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Mineralys Comparisons
Industry
Financing
Details
Mineralys Competitors (64)
One of Mineralys’s 64 competitors is Keros Therapeutics, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Keros Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Aldeyra Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Astria Therapeutics | Formerly VC-backed | Boston, MA | ||||
| Verve Therapeutics | Formerly VC-backed | Boston, MA | ||||
| Altimmune | Corporate Backed or Acquired | Gaithersburg, MD |
Mineralys Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Mineralys Patents
Mineralys Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4577216-A1 | Methods of treating hypertension in obese subjects | Pending | 23-Aug-2022 | ||
| AU-2023330154-A1 | Methods of treating hypertension with a combination of an aldosterone synthase inhibitor and a diuretic | Pending | 23-Aug-2022 | ||
| EP-4577217-A2 | Methods of treating hypertension with a combination of an aldosterone synthase inhibitor and a diuretic | Pending | 23-Aug-2022 | ||
| JP-2025503015-A | Method for treating hypertension by periodic inhibition of aldosterone synthase - patent application 20070223333 | Pending | 19-Jan-2022 | ||
| CA-3240577-A1 | Methods of treating hypertension by periodic suppression of aldosterone synthase | Pending | 19-Jan-2022 | A61K31/53 |
Mineralys Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Mineralys Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Mineralys ESG
Risk Overview
Risk Rating
Updated April, 03, 2024
29.01 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,697
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Biotechnology
Subindustry
of 368
Rank
Percentile
Mineralys FAQs
-
When was Mineralys founded?
Mineralys was founded in 2019.
-
Where is Mineralys headquartered?
Mineralys is headquartered in Radnor, PA.
-
What is the size of Mineralys?
Mineralys has 51 total employees.
-
What industry is Mineralys in?
Mineralys’s primary industry is Drug Discovery.
-
Is Mineralys a private or public company?
Mineralys is a Public company.
-
What is Mineralys’s stock symbol?
The ticker symbol for Mineralys is MLYS.
-
What is the current stock price of Mineralys?
As of 14-Jul-2025 the stock price of Mineralys is $15.02.
-
What is the current market cap of Mineralys?
The current market capitalization of Mineralys is $979M.
-
Who are Mineralys’s competitors?
Keros Therapeutics, Aldeyra Therapeutics, Astria Therapeutics, Verve Therapeutics, and Altimmune are some of the 64 competitors of Mineralys.
-
What is Mineralys’s annual earnings per share (EPS)?
Mineralys’s EPS for 12 months was -$3.73.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
